The economic burden of depression in the United States: how did it change between 1990 and 2000?

  title={The economic burden of depression in the United States: how did it change between 1990 and 2000?},
  author={Paul E. Greenberg and Ronald C. Kessler and Howard G. Birnbaum and Stephanie A. Leong and Sarah W. Lowe and Patricia A. Berglund and Patricia K Corey-Lisle},
  journal={The Journal of clinical psychiatry},
  volume={64 12},
BACKGROUND The economic burden of depression was estimated to be 43.7 billion dollars in 1990. A subsequent study reported a cost burden of 52.9 billion dollars using revised prevalence data and a refined workplace cost estimation approach. The objective of the current report is to provide a 10-year update of these estimates using the same methodological framework. METHOD Using a human capital approach, we developed prevalence-based estimates of 3 major cost categories: (1) direct costs, (2… 

Figures and Tables from this paper

Cost of depression among adults in Japan.
Depression imposes a substantial economic burden on Japanese society, which highlights the urgent need for policymakers to allocate resources toward implementing strategies that prevent and manage depression in the Japanese population.
The economic burden of adults with major depressive disorder in the United States (2005 and 2010).
Comorbid conditions account for the largest portion of the growing economic burden of MDD, and future research should analyze further these comorbidities as well as the relative importance of factors contributing to that growing burden.
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)
Although the total number of adults with MDD increased from 2010 to 2018, the incremental direct cost per individual declined, suggesting that substantial unmet treatment needs remain in this population.
Economic burden of depression in South Korea
The Korean society should increase the public health effort to prevent and detect depression in order to ensure that appropriate treatment is provided, and lead to a significant reduction in the total burden resulting from depression.
National trends in the treatment for depression from 1998 to 2007.
Although there was little change in the proportion of patients receiving antidepressants, treatment with psychotherapy has declined, and rapid increases in depression treatment from 1987 to 1997 were followed by more modest increases during the following decade.
Differences in medical care expenditures for adults with depression compared to adults with major chronic conditions.
This study shows that those with depression have comparable out-of-pocket expenses to those with other chronic diseases, but given their lower income levels, this may result in a more substantial financial burden.
Estimating the Economic Burden of Racial Health Inequalities in the United States
The authors estimate that eliminating health disparities for minorities would have reduced direct medical care expenditures by about $230 billion and indirect costs associated with illness and premature death by more than $1 trillion for the years 2003–2006 (in 2008 inflation-adjusted dollars).
Changing perceptions of depression: ten-year trends from the general social survey.
There have been changes in attitudes about the causes and treatments of depression among the American public in the past decade, with a shift toward a biological framework.


The economic burden of depression in 1990.
Depression imposes significant annual costs on society, and the true burden of this illness may be even greater than is implied by the estimate.
The economic burden of depression.
Cost of lost productive work time among US workers with depression.
The combined LPT burden among those with depression and the low level of treatment suggests that there may be cost-effective opportunities for improving depression-related outcomes in the US workforce.
National trends in the outpatient treatment of depression.
Between 1987 and 1997, there was a marked increase in the proportion of the population who received outpatient treatment for depression, and treatment became characterized by greater involvement of physicians, greater use of psychotropic medications, and expanding availability of third-party payment, but fewer outpatient visits and less use of Psychotherapy.
The economic impact of depression in a workplace.
  • D. J. Conti, W. Burton
  • Medicine, Psychology
    Journal of occupational medicine. : official publication of the Industrial Medical Association
  • 1994
The cost-utility of screening for depression in primary care.
BACKGROUND Depressive disorders are common in primary care and cause substantial disability, but they often remain undiagnosed. Screening is a frequently proposed strategy for increasing detection of
The economic burden of depression with painful symptoms.
More research is needed to assess the comprehensive economic impact that depression with painful physical symptoms can have on society, and more aggressive outreach may be warranted for patients with depression and comorbid pain to initiate treatment before symptoms are allowed to persist.
How can care for depression become more cost-effective?
Quality improvement measures that roughly follow practice guidelines for depression can improve outcomes and the value or cost-effectiveness of care, but at increased treatment costs; shifting patients away from mental health specialists decreases costs but worsens functioning outcomes.
The economic and social burden of depression.
Recent years have seen the development of a variety of new treatments that can be applied even in situations where highly specialized mental health staff are scarce, which make training in the use of new treatment methods of proven value and their wide application a public health priority and an ethical obligation.
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).
Notably, major depressive disorder is a common disorder, widely distributed in the population, and usually associated with substantial symptom severity and role impairment, and while the recent increase in treatment is encouraging, inadequate treatment is a serious concern.